The pathologic complete response open question in primary therapy

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 86-90

  Marchiò, Caterina ^a   Sapino, Anna ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN;

ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CARCINOMA IN SITU; HUMAN; HUMAN CELL; INTRADUCTAL CARCINOMA; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AXILLA; BREAST TUMOR; FEMALE; LYMPH NODE; LYMPH NODE METASTASIS; METHODOLOGY; MINIMAL RESIDUAL DISEASE; NEEDLE BIOPSY; PATHOLOGY; SEGMENTAL MASTECTOMY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BIOPSY, FINE-NEEDLE; BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL;

EID: 84855166704     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr025     Document Type: Article

References (25)

1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981, 47(1): 207-214.
2. Pinder SE, Provenzano E, Earl H, Ellis IO. Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology. 2007, 50(4): 409-417.
3. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993, 16(3): 223-228.
4. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995, 180(3): 297-306.
5. Penault-Llorca F, Abrial C, Raoelfils I, et al. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol. 2008, 39(8): 1221-1228.
6. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990, 82(19): 1539-1545.
7. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002, 20(6): 1456-1466.
8. Symmans WF, Peintinger F, Hatzois C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007, 25(28): 4414-4422.
9. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003, 12(5): 320-327.
10. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002, 95(4): 681-695.
11. Sahoo S, Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med. 2009, 133(4): 633-642.
12. Sabel MS, Newman LA. The utility of ultrasonography in the management of breast cancer. Am J Oncol Rev. 2003, 2(6): 296-298.
13. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007, 25(19): 2650-2655.
14. Castellano I, Marchio C, Tomatis M, et al. Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study. Mod Pathol. 2010, 23(2): 260-269.
15. Khan A, Sabel MS, Nees A, et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol. 2005, 12(9): 697-704.
16. Kilbride KE, Lee MC, Nees AV, et al. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. Ann Surg Oncol. 2008, 15(11): 3252-3258.
17. Sapino A, Cassoni P, Zanon E, et al. Ultrasonographically-guided fine-needle aspiration of axillary lymph nodes: role in breast cancer management. Br J Cancer. 2003, 88(5): 702-706.
18. Brown AS, Hunt KK, Shen J, et al. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer. 2010, 116(12): 2878-2883.
19. Loya A, Guray M, Hennessy BT, et al. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer. 2009, 115(8): 1605-1612.
20. Purushotham A, Pinder S, Cariati M, Harries M, Goldhirsch A. Neoadjuvant chemotherapy: not the best option in estrogen receptor-positive, HER2-negative, invasive classical lobular carcinoma of the breast? J Clin Oncol. 2010, 28(22): 3552-3554.
21. Precht LM, Lowe KA, Atwood M, Beatty JD. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. Breast J. 2010, 16(4): 362-368.
22. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007, 13(8): 2329-2334.
23. Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004, 10(19): 6622-6628.
24. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004, 40(2): 205-211.
25. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005, 11(16): 5678-5685.